Correspondence 0001104659-22-128976 from Edesa Biotech, Inc. (EDSA)
Edesa Biotech, Inc.
Date: Dec. 21, 2022 · CIK: 0001540159 · Accession: 0001104659-22-128976
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-268847
Letter
Edesa Biotech, Inc.
100 Spy Court
Markham, Ontario, Canada L3R 5H6
December 21, 2022
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Edesa Biotech, Inc.
Registration Statement on Form S-3 (File No. 333-268847)
Filed on December 16, 2022
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, Edesa Biotech, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 4:05 p.m., Eastern Time, on December 23, 2022, or as soon as practicable thereafter.
Please call Tracy Buffer of Lowenstein Sandler LLP at (973) 597-2434 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
EDESA BIOTECH, INC.
Show Raw Text
CORRESP
1
filename1.htm
Edesa Biotech, Inc.
100 Spy Court
Markham, Ontario, Canada L3R 5H6
December 21, 2022
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Edesa Biotech, Inc.
Registration Statement on Form S-3 (File No. 333-268847)
Filed on December 16, 2022
Ladies and Gentlemen:
In accordance with Rule 461
under the Securities Act of 1933, as amended, Edesa Biotech, Inc. (the “Company”) hereby requests that the above-referenced
Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission
at 4:05 p.m., Eastern Time, on December 23, 2022, or as soon as practicable thereafter.
Please call Tracy Buffer of
Lowenstein Sandler LLP at (973) 597-2434 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
EDESA BIOTECH, INC.
By: /s/ Kathi Niffenegger
Name: Kathi Niffenegger
Title: Chief Financial Officer